stockrowNeurocrine Biosciences, Inc. (NBIX) vs Takeda Pharmaceutical Co. (TAK)
- Neurocrine Biosciences, Inc. NBIX 160.47 −3.36%
- Takeda Pharmaceutical Co. TAK 21.25 +0.90%
Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Co. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $67.7B against $16.2B — 4.2× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 23.0× against 32.0×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 0.66%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs 7.12%) and the higher return on invested capital (17.7% vs 0.00%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 16 and Takeda Pharmaceutical Co. on 6.
Valuation
Profitability
| Metric | NBIX | TAK | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.75% | 65.85% | 53.51% |
| Operating margin | 23.96% | 11.61% | 0.00% |
| Net margin | 18.98% | 7.12% | (2.45%) |
| Free cash flow margin | 28.09% | 0.00% | 0.00% |
| Return on equity | 20.41% | 0.00% | (0.80%) |
| Return on assets | 14.20% | 0.00% | (1.67%) |
| Return on invested capital | 17.65% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack